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Abstract
Background: Many blood biomarkers have a positive association with stroke outcome, but adding blood biomarkers to the
National Institutes of Health Stroke Scale (NIHSS) did not significantly improve its discriminatory ability. We investigated the
association of the CHA2DS2-VASc score with unfavourable functional outcome (defined as a 30-day modified Rankin Scale
[mRS] $3) in patients presenting with acute ischemic stroke (AIS), and examined whether the addition of blood biomarkers
(troponin I [TnI], fibrinogen, C-reactive protein [CRP]) affects the model discriminatory ability.
Methods: We conducted an observational single-centre study of consecutive patients with AIS. All patients were admitted
to hospital within 24 hours from the neurological symptoms onset.
Results: Of 240 patients (mean age 70.068.9 years), unfavourable 30-day outcome occurred in 92 (38.3%). Patients with
mRS$3 were older and more likely to have atrial fibrillation or other comorbidities (all p,0.001). They had higher levels of
CRP, fibrinogen, TnI and higher CHA2DS2-VASc and CHADS2 scores (all p,0.05). The adjusted CHA2DS2-VASc score had
excellent predictive ability for poor stroke outcome (c-statistic 0.982;95%CI,0.964–1.000, p,0.001). Whilst CRP had the
highest sensitivity (83.7%), cardiac TnI was the most specific (97.3%) for prediction of poor stroke outcome (cut-off: .
0.09mg/L). Compared with each of these biomarkers, CHA2DS2-VASc score had significantly better predictive ability for poor
stroke outcome (c-statistic for CRP, Fibrinogen and TnI was 0.853;95%CI,0.802–0.895, 0.848;95%CI,0.796–0.891, and
0.792;95%CI,0.736–0.842, all p,0.001, respectively, versus 0.932;95%CI,0.892–0.960, p,0.001 for the CHA2DS2-VASc, all p for
the comparisons,0.01). There was no significant difference in the predictive ability of the CHA2DS2-VASc score vs.
combinations of the CHA2DS2-VASc and TnI or TnI, fibrinogen and CRP (z statistic 0.369, p = 0.7119; integrated
discrimination index 0.00801 and 0.00172, respectively, both p.0.05).
Conclusions: The CHA2DS2-VASc score alone reliably predicts 30-day unfavourable outcome of stroke. Adding blood
biomarkers to the CHA2DS2-VASc score did not significantly increase the predictive ability of the model.
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Introduction
The early prediction of death or disability following acute
ischemic stroke (AIS) presently relies upon clinical variables such
as age and stroke severity, as measured by the National Institutes
of Health Stroke Scale (NIHSS) [1,2]. These predictions are often
broadly similar to the experienced stroke physicians clinical
judgement [3], and continuous efforts are being made to improve
the predictive ability of validated prognostic clinical variables by
adding various biomarkers (whether blood, urine or imaging-
based) to the original models based on clinical risk factors.
Many blood-based biomarkers have been extensively studied as
potential predictors of poor stroke outcome. However, most of the
associations were relatively weak and no single class of biomarkers
had a stronger association than the others [4]. Nevertheless, the
effect of cardiac biomarkers was consistent, and a number of
studies found an increased mortality in stroke patients with
elevated cardiac troponin I (TnI) [5–7] or troponin T (TnT) [8,9].
Indeed, adding high-sensitivity TnT to several clinical variables
including age and stroke severity resulted in incremental
discrimination and reclassification of patients in one study [10],
whilst another study showed that positive association of many
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biomarkers (including TnT) became statistically insignificant after
adjustment for age and baseline NIHSS, and adding the N-
Terminal pro-BNP or Interleukin-6 (the only statistically signifi-
cant biomarkers after the adjustment) to age plus NIHSS made no
significant difference to the model discriminatory ability [11].
A recent study showed that the CHADS2 and CHA2DS2-VASc
scores, which were originally formulated for risk assessment of
stroke in patients with atrial fibrillation (AF) [12], were good
predictors of 5-year outcomes in non-AF patients with AIS [13].
The CHA2DS2-VASc score correlated well with stroke severity in
AF patients [14], and was a multivariate predictor of 90-day stroke
outcome, independently of baseline NIHSS values [15].
The aim of the present study was to investigate the association
of the CHA2DS2-VASc score with poor short-term (30-day)
functional outcome in patients with AIS, regardless of the heart
rhythm, and to examine whether the addition of TnI affects the
model discriminatory ability regarding the poor short-term
outcome of AIS. We tested the hypothesis that the CHA2DS2-
VASc score is significantly associated with poor short-term stroke
outcome and that adding TnI improves the model predictive
ability.
Materials and Methods
Patient selection and study design
An observational single-centre study of consecutive patients
presenting with AIS who were admitted to hospital during 2010
was conducted in the University Clinical Centre Gracanica. All
patients gave written informed consent, and the University
Clinical Centre Gracanica review board approved the study.
All patients were admitted to hospital within 24 hours from the
neurological symptoms onset. The diagnosis of AIS was estab-
lished using the clinical evaluation and computed tomography
(CT) of the brain within the first 24 hours of the event onset in all
patients, and during hospitalization as needed. Patients with
unclear timing of symptoms onset and those with haemorrhagic
stroke or transient ischemic attack (TIA) were excluded (TIA was
defined as a transient episode of neurological dysfunction caused
by focal brain, spinal cord, or retinal ischemia, without acute
infarction) [16]. Patients with a history of prior myocardial
infarction (MI) or coronary artery disease (CAD) documented by
coronary angiography, as well as patients with symptoms and
electrocardiographic (ECG) signs suggestive of transient myocar-
dial ischemia or an acute coronary syndrome (ACS) were excluded
from this study in an attempt to avoid the confounding interplay of
elevated cardiac troponin, possible acute MI and stroke regarding
the 30-day functional stroke outcome.
All patients underwent a detailed history and physical exam-
ination, blood and urine testing, 12-channel ECG recording, chest
radiography and transthoracic echocardiography (TTE). A 24-
hour ECG Holter monitoring was performed in all patients within
the first three days of hospitalization. Cardiac diseases and non-
cardiac disorders were noted in the presence of a detailed medical
record or a self-reported history of the disease, or when standard
diagnostic criteria were fulfilled at diagnostic evaluation. Patients
with advanced mitral or aortic valve disease awaiting surgical valve
repair were excluded from the study.
Blood biomarkers
Blood samples were taken upon admission to hospital and
processed within 1 hour. In addition to routine biochemistry, C-
reactive protein (CRP), cardiac TnI and D-dimer were measured
in each patient. CRP was measured by latex-enhanced nephe-
lometry with the use of high-sensitivity assays on the Behring
Nephelometer II analyzer (Dade-Behring Diagnostics, Deerfield,
IL) with a lower detection limit of 0.2 mg/L and interassay CVs of
5–9%. TnITnI and D-dimer were measured by ELFA (Enzyme
Linked Fluorescent Assay) method (VIDAS TNI ULTRA and
VIDAS D-Dimer Exclusion Assay, by BioMerieux Clinical
Diagnostics), with a lower detection limit of 0.01mg/L and
measurement range of 0.01–30mg/L (10% CV [Coefficient of
Variation] point 0.11mg/L) for TnI, and a lower detection limit of
#0.045mg/mL and measurement range of 0.045–10mg/mL (the
clinical cut-off 0.5mg/mL) for D-dimer. In all patients, a creatinine
clearance test was done on a 24-hour urine sample.
Stroke and bleeding risk scores
All stroke and bleeding scores were calculated on admission to
hospital, according to the clinical status prior to acute stroke onset.
The CHADS2 score was calculated by giving 1 point each for
congestive heart failure, hypertension, age.75 years and diabetes,
and 2 points for prior stroke or TIA, the CHA2DS2-VASc by
giving 1 point each for congestive heart failure/left ventricular
systolic dysfunction (left ventricular ejection fraction #40%),
hypertension, diabetes, peripheral vascular disease (including prior
MI or complex aortic plaque), age 65–74 years and female gender,
and 2 points for prior stroke or TIA and for age $75 years, and
the HAS-BLED by giving 1 point each for hypertension, abnormal
renal function, abnormal liver function, prior stroke, labile INRs
(International Normalized Ratio), age .65 years, concomitant
drug (aspirin or non-steroidal anti-inflammatory drugs) or alcohol
use [17].
Combined scores
Combined scores were formulated using the CHA2DS2-VASc
score and TnI or CRP or fibrinogen or all three biomarkers, thus
resulting in the CHA2DS2-VASc-T, CHA2DS2-VASc-CRP,
CHA2DS2-VASc-F and CHA2DS2-VASc-CRPFT score, respec-
tively.
Short-term stroke outcomes
In-hospital mortality was defined as death from any cause
during the index hospitalization. A 30-day mRS was calculated as
a measure of functional neurological outcome of AIS; the scale is
graded from 0 to 6, with 0 for patients without any symptom, 3–5
for increasing disability and 6 for death, and a mRS of$3 signifies
an unfavourable stroke outcome [18].
None of the patients received thrombolytic therapy, since it was
not available in our centre during the study period. Nevertheless,
symptomatic haemorrhagic transformation (sHT) of AIS, defined
as a rapid significant clinical deterioration temporally related to
HT documented by CT-scan or autopsy, was regarded as a serious
adverse event in the evolution of AIS [19,20].
Statistical analyses
Following a test of statistical normality, continuous variables are
presented as mean (6SD), or with a skewed distribution as median
with interquartile range (IQR, 25th to 75th quartile). Categorical
variables are reported as counts with percentages. The Student t-
test was used for comparison of continuous variables with normal
distribution, and Mann-Whitney test for continuous variables with
skewed distribution (Table 1). Differences in categorical variables
were tested by Chi-square test. Since blood biomarkers’ levels had
skewed distribution, a logarithm transformation was used, and all
logistic regression analyses were performed (and reported) in two
ways: first, a biomarker was entered as a log transformed
continuous independent variable and then, the analysis was
CHA2DS2-VASc Score Alone Predicts Stroke Outcome
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Table 1. Baseline characteristic of patients with acute ischemic stroke according to favourable (mRS,3) or unfavourable 30-day
functional stroke outcome (mRS$3), including in-hospital death.
A. Baseline parameters All patients mRS,3 mRS$3 P
N=240 148 (61.7) 92 (38.3)
Age (years) 70.068.9 67.268.1 74.568.4 ,0.001
Males 139 (57.9) 77 (52.0) 62 (67.4) 0.022
Body mass index 29.262.3 29.262.2 29.162.4 0.737
Systolic blood pressure (mmHg) 150 (140–180) 150 (140–170) 150 (115–190) 0.606
Diastolic blood pressure (mmHg) 90 (80–105) 90 (80–105) 90 (80–110) 0.151
Heart rate (beats per minute) 80 (75–90) 80 (75–90) 90 (75–95) 0.791
Current smoker 134 (55.8) 83 (56.1) 51 (55.4) 1.000
Excessive alcohol consumption 36 (15.0) 29 (19.6) 7 (7.6) 0.015
NYHA class (mean) 2.260.4 2.160.3 2.360.6 ,0.001
NYHA class I-II 202 (84.2) 136 (91.9) 66 (71.8) ,0.001
NYHA class III-IV 38 (20.2) 12 (8.1) 28 (28.2) ,0.001
Comorbidities:
Atrial fibrillation 88 (36.7) 35 (23.6) 53 (57.6) ,0.001
Hypertension 178 (74.2) 107 (72.3) 71 (77.2) 0.450
Diabetes mellitus 72 (30.0) 28 (18.9) 44 (47.8) ,0.001
Heart failure 18 (7.5) 3 (2.0) 15 (16.3) ,0.001
Chronic kidney disease 11 (4.6) 6 (4.1) 5 (5.4) 0.753
Prior stroke (any)/TIA 24 (10.0) 1 (0.7) 23 (25.0) ,0.001
Stroke and bleeding risk assessment scores*
CHADS2 (mean) 1.8661.1 1.3060.64 2.7761.07 ,0.001
median (IQR) 2.0 (1.0–2.0) 1.0 (1.0–2.0) 3.0 (2.0–3.8)
CHA2DS2-VASc (mean) 3.6461.66 2.7061.10 5.1461.25 ,0.001
median (IQR) 3.5 (3.0–5.0) 3.0 (2.0–3.0) 5.0 (4.0–6.0)
HAS-BLED (mean) 2.4561.07 2.0860.90 3.0461.06 ,0.001
median (IQR) 2.0 (2.0–3.0) 2.0 (1.0–3.0) 3.0 (2.0–4.0)
Echocardiographic parameters:
Left atrial diameter (cm) 4.2860.64 4.0860.53 4.6160.67 ,0.001
Left atrial volume index 42.9610.9 39.368.8 48.7611.4 ,0.001
emsp;Left ventricular ejection fraction 56.368.9 58.765.6 52.4611.5 ,0.001
Left ventricular end-systolic diameter (cm) 3.7560.42 3.6560.31 3.9160.51 ,0.001
Mitral annulus calcification 62 (25.8) 5 (3.4) 57 (62.0) ,0.001
B.Treatment at discharge
Beta blockers 110 (45.8) 63 (42.6) 47 (51.1) 0.231
Calcium antagonists 149 (62.1) 92 (62.2) 57 (61.0) 1.000
Digoxin 30 (12.5) 10 (6.8) 20 (21.7) 0.001
Amiodarone 11 (4.6) 3 (2.0) 8 (8.7) 0.024
ACEIs 134 (55.8) 98 (66.2) 36 (39.1) ,0.001
ARBs 77 (32.1) 51 (34.5) 26 (28.3) 0.394
Diuretics 116 (48.3) 56 (37.8) 60 (65.2) ,0.001
Statins 68 (28.3) 48 (32.4) 20 (21.7) 0.079
Aspirin 154 (64.2) 90 (60.8) 64 (69.6) 0.213
Values are presented as n (%) or mean 6 standard deviation or median with interquartile range (IQR).
mRS, modified Rankin Scale (patients who died were assigned a mRS of 6); NYHA, New York Heart Association; TIA, transient ischemic attack; CHADS2, congestive heart
failure, hypertension, age $75 years, diabetes mellitus, prior stroke or TIA; CHA2DS2-VASc, congestive heart failure or left ventricular ejection fraction #40%,
hypertension, age $75 years, diabetes mellitus, prior stroke or TIA, vascular disease (including myocardial infarction and peripheral artery disease), age .65 years,
female gender; HAS-BLED, hypertension, abnormal renal or liver function, prior stroke, labile INRs (International Normalized Ratio), elderly (.65 years), concomitant
drugs or alcohol use; MAC, mitral annulus calcification; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
doi:10.1371/journal.pone.0106439.t001
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Table 2. Baseline blood biomarkers levels in patients with acute ischemic stroke according to favourable (mRS,3) or unfavourable
30-day functional stroke outcome, including in-hospital death (mRS$3).
Blood biomarkers All patients mRS,3 mRS$3 P
N=240 148 (61.7) 92 (38.3)
C-reactive protein, mean 16.70617.89 7.96610.75 30.77618.14 ,0.001
C-reactive protein, median (IQR) 4.0 (3.0–32.5) 4.0 (3.0–4.0) 35.0 (16.0–44.0) ,0.001
Quartile 1: ,3.0 18 (7.5) 16 (10.8) 2 (2.2)
Quartile 2: 3.0–3.9 49 (20.4) 44 (29.7) 5 (5.4)
Quartile 3: 4.0–32.4 113 (47.1) 78 (52.7) 35 (38.0)
Quartile 4: $32.5 60 (25.0) 10 (6.8) 50 (54.3)
Fibrinogen, mean 4.1562.12 3.2561.17 5.6162.47 ,0.001
Fibrinogen, median (IQR) 3.50 (2.90–5.00) 3.15 (2.50–3.60) 5.40 (3.90–6.80) ,0.001
Quartile 1: ,2.9 57 (23.8) 51 (34.5) 6 (6.5)
Quartile 2: 2.9–3.4 51 (21.2) 44 (29.7) 7 (7.6)
Quartile 3: 3.5–4.9 68 (28.3) 44 (29.7) 24 (26.1)
Quartile 4: $5.0 64 (26.7) 9 (6.1) 55 (59.8)
Cardiac TnI, mean 0.21760.453 0.0660.10 0.46860.649 ,0.001
Cardiac TnI, median (IQR) 0.06 (0.03–0.09) 0.04 (0.02–0.07) 0.20 (0.05–0.65) ,0.001
Quartile 1: ,0.03 47 (19.6) 42 (28.4) 5 (5.4)
Quartile 2: 0.03–0.059 70 (29.2) 51 (34.5) 19 (20.7)
Quartile 3: 0.06–0.089 49 (20.4) 36 (24.3) 13 (14.1)
Quartile 4: $0.09 74 (30.8) 19 (12.8) 55 (59.8)
D-dimer, mean 0.6160.85 0.4560.68 0.8761.02 ,0.001
D-dimer, median (IQR) 0.24 (0.18–0.80) 0.22 (0. 17–0.32) 0.50 (0.19–1.24) ,0.001
Quartile 1: ,0.180 56 (23.3) 41 (27.7) 15 (16.3)
Quartile 2: 0.180–0.234 64 (26.7) 41 (27.7) 23 (25.0)
Quartile 3: 0.235–0.799 58 (24.2) 44 (29.7) 14 (15.2)
Quartile 4: $0.800 62 (25.8) 22 (14.9) 40 (43.5)
WBC, mean 8.2161.68 7.9961.76 8.5161.47 0.008
WBC, median (IQR) 8.1 (7.0–9.0) 7.8 (6.9–9.0) 8.80 (7.70–9.68) 0.072
Quartile 1: ,7.0 50 (20.8) 38 (25.7) 12 (13.0)
Quartile 2: 7.0–8.0 69 (28.7) 43 (29.1) 26 (28.3)
Quartile 3: 8.1–8.9 38 (15.8) 23 (15.5) 15 (16.3)
Quartile 4: $9.0 83 (34.6) 44 (29.7) 39 (47.0)
CrCl, mean 55.3567.60 56.3667.35 53.7367.77 0.009
CrCl, median (IQR) 56.00 (51.00–60.00) 56.00 (53.25–60.00) 55.00 (48.25–59.00) 0.020
Quartile 1: ,51 58 (24.2) 27 (18.2) 31 (33.7)
Quartile 2: 51–55 61 (25.4) 36 (24.3) 25 (27.2)
Quartile 3: 56–59 52 (21.7) 38 (25.7) 14 (15.2)
Quartile 4: $60 69 (28.7) 47 (31.8) 22 (23.9)
Total cholesterol, mean 5.7161.17 5.5761.09 5.9161.26 0.025
Total cholesterol, median (IQR) 5.35 (5.00–6.50) 5.20 (5.00–6.00) 6.00 (5.00–6.80)
HDL, mean 1.0460.46 1.0260.31 1.0760.63 0.416
HDL, median (IQR) 1.00 (0.90–1.00) 1.00 (0.93–1.05) 1.00 (0.90–1.00)
LDL, mean 3.9561.17 3.8361.06 4.1461.31 0.043
LDL, median (IQR) 3.80 (3.20–4.70) 3.60 (3.20–4.36) 4.40 (3.30–4.98)
Hematocrit, mean 0.4160.07 0.4260.06 0.4060.07 0.040
Haematocrit, median (IQR) 0.41 (0.38–0.45) 0.42 (0.39–0.45) 0.40 (0.34–0.46)
CHA2DS2-VASc Score Alone Predicts Stroke Outcome
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performed with biomarker levels grouped to quartiles (the latter
was done to facilitate a meaningful clinical interpretation of the
results), Table 2 and 3. The CHADS2, CHA2DS2-VASc and
HAS-BLED scores and all combined scores were entered as
continuous variables in all models. Following unadjusted analyses
(Table 4), the adjustment was done for each analysis as detailed in
the Table 5 legend. Unfavourable 30-day functional outcome of
AIS, including in-hospital death (i.e., a mRS of $3) was the
dependent variable in all analyses.
The c-statistic, a measure of the area under the receiver-
operator characteristic (ROC) curve, was used to quantify the
predictive validity of each biomarker, the CHADS2, CHA2DS2-
VASc and HAS-BLED and the combined scores, and tested the
hypothesis that these models performed significantly better than
chance (indicated by a c-statistic $0.5). In addition to model
discriminatory ability (the ROC curve analysis), model calibration
of each adjusted model was tested by the Hosmer-Lemeshow
goodness-of-fit test, which assesses whether the observed event
rates match expected event rates in subgroups of the model
population. Explanatory power was tested using the pseudo- R 2
statistic according to the ‘‘Nagelkerke R2 ’’ to assess the degree to
which the model explained the variance of the binary outcome.
Pairwise comparisons of the ROC curves were performed using
the approach of DeLong, DeLong and Clarke-Pearson [21] and
the MedCalc statistical software – version 12.7.0.0. Finally, using
the Stata 11 software, we calculated the integrated discrimination
index (IDI), which is equivalent to the difference in discrimination
slopes [22]. All other statistical analyses were performed using
SPSS 20.0 software package (SPSS Inc., Chicago, Illinois). A value
of P ,0.05 was considered statistically significant in all analyses.
Results
Of 273 patients with AIS, 33 were excluded from this study
because of the history of CAD or an acute MI during the
hospitalization for AIS. These patients were not significantly older
as compared to those without clinically evident CAD (73.2610.1
vs. 70.068.9 years, respectively, p = 0.064), but they had higher
CHADS2 and CHA2DS2-VASc scores (2.8261.21 vs. 1.8661.10
and 4.9161.65 vs. 3.6461.66, respectively, both p,0.001) and
mean NYHA class (2.660.8 vs. 2.260.4, p,0.001), lower CrCl
(50.969.3 vs. 55.467.6, p = 0.002) and higher CRP levels
(27.3616.6616.7617.9, p = 0.001), whilst there was no significant
difference in the mean TnI levels at baseline (0.3260.35 vs.
0.2260.45, p = 0.266) or the prevalence of AF (18 [54.5%] vs. 88
[36.7%], p = 0.057). An unfavourable 30-day stroke outcome
occurred more frequently in the CAD patients (28 [84.8] vs. 92
[38.3]%, p,0.001).
Of 240 patients included in this study (Table 1), unfavourable
30-day functional stroke outcome occurred in 92 patients (38.3%),
including in-hospital death in 21 patients (8.8%). Patients with
mRS$3 were older, more often males and more likely to have AF,
diabetes mellitus, HF, prior stroke/TIA, mitral annulus calcifica-
tion, larger left atrial size or lower left ventricular ejection fraction
(all p,0.001). They were more often prescribed diuretics and
digoxin, and less frequently received angiotensin-converting
enzyme inhibitors (all p,0.05).
Blood biomarkers
Patients with 30-day mRS$3 had higher levels of CRP,
fibrinogen, TnI, D-dimer, total cholesterol and LDL, higher white
blood cell count, and lower hematocrit and CrCl (all p,0.05,
Table 2]. Significant associations of blood biomarkers with
unfavourable 30-day stroke outcome, predictive ability of each
biomarker and pairwise comparisons of biomarker predictive
abilities are shown in Table 3 and Figure 1 (upper left panel).
CRP, fibrinogen and TnI had significantly better predictive ability
compared with D-dimer, CrCl or total cholesterol (all p,0.001),
whilst there were no significant differences among the first three
biomarkers (Table 3 and Figure 1).
Sensitivity, specificity and cut-off values for cardiac CRP,
fibrinogen, TnI and D-dimer are shown in Figure 2. Whilst CRP
had the highest sensitivity (83.7%), cardiac TnI was the most
specific (97.3%) for prediction of unfavourable short-term stroke
outcome, with cut-off value of .0.09mg/L (Figure 2).
CHA2DS2-VASc, CHADS2 and HAS-BLED scores
Patients with unfavourable short-term functional stroke out-
come had higher values of all three scores, compared with patients
with mRS,3. The crude association of CHA2DS2-VASc,
CHADS2 and HAS-BLED scores with unfavourable 30-day
outcome, predictive ability of each score and pairwise comparison
of the scores predictive abilities are shown in Table 3 and Figure 1
(upper right panel). The CHA2DS2-VASc score had significantly
better predictive ability for unfavourable short-term stroke
outcome than the CHADS2 or HAS-BLED score (both p,
0.001) [Table 3 and Figure 1]. Within the CHA2DS2-VASc score,
age, diabetes mellitus and prior stroke or TIA were significantly
associated with unfavourable 30-day outcome (Odds Ratio [OR]
1.2; 95% Confidence Interval [CI] 1.1–1.2, OR 6.3; 95%CI 2.8–
14.0 and OR 47.7; 95%CI 5.2–439.0, respectively, all p,0.001).
The CHA2DS2-VASc score had better sensitivity and specificity
than the CHADS2 or HAS-BLED score (93.5% vs. 92.4% vs.
71.7% and 77.0% vs. 61.5% vs. 69.6%, respectively, all p,0.05)
for unfavourable short-term functional outcome of AIS.
CHA2DS2VASc-score versus CRP, fibrinogen or cardiac TnI
Pairwise comparisons of predictive abilities of the CHA2DS2-
VASc score versus CRP, fibrinogen or TnI are shown in Table 3
Table 2. Cont.
Blood biomarkers All patients mRS,3 mRS$3 P
N=240 148 (61.7) 92 (38.3)
Haemoglobin, mean 134.13618.71 135.03619.63 132.68617.13 0.084
Haemoglobin, median (IQR) 135 (127–145.75) 136.50 (129–146) 134 (125.50–145)
Values are presented as n (%) or mean 6 standard deviation or median with interquartile range (IQR). C-reactive protein is given in mg/L, fibrinogen in g/L, TnI in mg/L
and D-dimer in mg/mL.
mRS, modified Rankin Scale (patients who died were assigned a mRS of 6); WBC, white blood cell count; CrCl, creatinine clearance; HDL, high density lipoprotein; LDL,
low density lipoprotein.
doi:10.1371/journal.pone.0106439.t002
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and Figure 1 (lower left panel). Compared with each of these
biomarkers, CHA2DS2-VASc score had significantly better
predictive ability for unfavourable 30-day functional stroke
outcome (all p,0.01).
Combined scores (CHA2DS2VASc plus CRP or fibrinogen
or TnI and CHA2DS2VASc plus all three biomarkers)
As above, the cut-off values for increased risk of unfavourable
stroke outcome in our cohort were determined for each of three
biomarkers, and 1 point was added to the CHA2DS2-VASc score
if the level of a given biomarker in a given patient exceeded the
cut-off value.
On the unadjusted analyses, all combined scores (Table 4) were
significantly associated with unfavourable 30-day functional stroke
outcome (all p,0.001), and the combination of CHA2DS2-VASc
with TnI had the best predictive ability (c-statistic 0.955;
95%CI,0.921–0.978, p,0.001). All unadjusted combined scores
were slightly better than unadjusted CHA2DS2-VASc alone (all
p#0.05). The combination of CHA2DS2-VASc with all three
biomarkers (CHA2DS2-VASc-CRPFT) had similar predictive
ability as each of the combinations of CHA2DS2-VASc score
with a single biomarker (all p$0.05) [Table 4 and Figure 1 (lower
right panel)].
Following adjustment (see Table 5 legend), only TnI, fibrino-
gen, CHA2DS2-VASc, CHA2DS2-VASc-T and CHA2DS2-VASc-
CRPFT score remained significantly associated with unfavourable
30-day stroke outcome (Table 5). The pairwise comparisons of
their predictive abilities are shown in Table 5 and Figure 3.
Adjusted CHA2DS2-VASc and CHA2DS2-VASc-T (or CHA2DS2-
VASc-CRPFT) score models had significantly better predictive
ability than TnI alone, whilst there was no significant difference
between adjusted CHA2DS2-VASc vs. CHA2DS2-VASc-T score
(or the CHA2DS2-VASc-CRPFT) models (all p.0.05), with
statistically insignificant discrimination improvement when adding
TnI only or CRP plus fibrinogen plus TnI to the ‘classic’ CHA2DS2-
VASc score (Table 5).
Analyses including patients with clinically evident CAD
Analyses of the whole AIS cohort (n = 273) including patients
with clinically evident CAD (n = 33) yielded essentially identical
results. Patients with unfavourable short-term functional stroke
outcome had higher values of all three scores, compared with
patients with mRS,3 (mean CHADS2 of 2.8361.10 vs.
1.3160.64, mean CHA2DS2-VASc of 5.1761.31 vs. 2.7161.10
and mean HAS-BLED score of 3.0661.06 vs. 2.0860.91,
respectively, all p,0.001).
All 3 scores were significantly associated with unfavourable 30-
day stroke outcome on the univariate analyses (CHADS2: OR
11.9, 95%CI 6.3–22.4; CHA2DS2-VASc: OR 7.6, 95%CI 4.7–
12.2; HAS-BLED: OR 2.8, 95%CI 2.1–3.8, all p,0.001), whilst
only the CHA2DS2-VASc was significantly associated with
unfavourable 30-day stroke outcome in the multivariable analysis
including all 3 scores (OR 7.6, 95%CI 4.7–12.2). All 3 scores had a
good predictive ability for unfavourable short-term stroke outcome
(CHADS2: c-statistic 0.882, 95%CI 0.841–0.922; CHA2DS2-
VASc: c-statistic 0.932, 95%CI 0.91–0.962; HAS-BLED: c-
statistic 0.754, 95%CI 0.696–0.812, all p,0.001), but the
CHA2DS2-VASc score had significantly better predictive ability
compared with the CHADS2 or HAS-BLED score (z-statistic
4.256 and 5.648, respectively, both p,0.001). Within the
CHA2DS2-VASc score, age, diabetes mellitus, prior stroke or
TIA and CAD were significantly associated with unfavourable
short-term stroke outcome (OR [95%CI]: 1.2 [1.1–1.2], 5.3 [2.5–
11.1], 43.9 [5.0–384.3] and 8.5 [2.3–31.5], respectively, all p #
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0.001). Other analyses with the biomarkers and combined scores
also yielded essentially identical results as shown for the AIS cohort
without clinically overt CAD (data not shown).
Discussion
In the present study, we show that the CHA2DS2-VASc score
reliably predicts a short-term, 30-day unfavourable outcome of
AIS (regardless of the presence or absence of AF), and that adding
the high-sensitivity TnI (or fibrinogen or CRP, or all three
biomarkers) to CHA2DS2-VASc score does not further improve
the prediction. These findings could be of clinical relevance, as the
pre-stroke CHA2DS2-VASc score can be easily calculated in most
circumstances, thus offering a simplified, quick and reliable initial
risk assessment in the acute stroke setting.
The CHA2DS2-VASc score has been originally developed to
refine the assessment of stroke risk in patients with non-valvular
AF [12], and was subsequently validated in a number of AF
cohorts [23–27]. Recently, it was tested in a non-AF cohort and
was comparably successful for stroke prediction in that cohort as in
AF patients [28]. In addition, many recent studies showed that the
CHA2DS2-VASc score was associated with poor clinical out-
comes, including mortality, in various cohorts of cardiovascular
patients [29]. Furthermore, the CHA2DS2-VASc score has been
shown to correlate well with stroke severity in AF patients [14],
and to be a multivariable predictor of 90-day stroke outcome,
independently of baseline NIHSS values [15]. A recent study
found that the CHADS2 and CHA2DS2-VASc scores also were
good predictors of 5-year outcomes in non-AF patients with AIS
[13]. However, the association of the CHADS2 and CHA2DS2-
VASc scores with 30-day outcome of AIS has not been previously
investigated prospectively [30,31].
Our findings suggest that the CHA2DS2-VASc score reliably
predicts poor 30-day stroke outcome, with significantly better
predictive ability compared to the CHADS2 score. Indeed, on the
logistic regression analysis which accounted for blood biomarkers,
Figure 1. Receiver-operator characteristic analyses of the biomarkers and stroke risk scores predictive ability for unfavourable 30-
day outcome of ischemic stroke and pairwise comparisons (Table 2).
doi:10.1371/journal.pone.0106439.g001
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the presence of AF and a number of clinical/echocardiographic
parameters, the model with CHA2DS2-VASc score had an
excellent predictive ability for poor short-term stroke outcome
(c-statistic of 0.982). Indeed, even the unadjusted CHA2DS2-VASc
score predictive ability was very good, with c-statistic of 0.932.
Increasing body of evidence shows that a number of blood
biomarkers are significantly associated with various clinical events
[4,11,32,33,34,35]. For example, a recent large biomarker
substudy of the RE-LY trial (Randomized Evaluation of Long-
Term Anticoagulation Therapy) showed that elevated TnI and
NT-proBNP were independently related to increased risks of
stroke and mortality and significantly improved risk prediction in
AF patients beyond currently used clinical tools (i.e., the CHADS2
and CHA2DS2-VASc scores) [36]. However, the substudy had not
investigated the association of biomarkers with stroke outcomes in
patients who suffered AIS during follow-up. A recent systematic
review of diagnostic and prognostic role of blood biomarkers in
AIS highlighted blood glucose and fibrinogen levels as the most
consistent predictors of poor functional outcome of stroke [33].
Nonetheless, studies on biomarkers generally suffer from several
shortcomings, including relatively small number of patients,
variable analytical techniques and interpretation of results (which
may limit the reproducibility), different study population risk
profiles, etc. Indeed, a recent study of 270 patients with AIS or
TIA, which investigated the prognostic role of 18 blood
biomarkers (including glucose, fibrinogen, troponin T, CRP, D-
dimer, leukocytes, etc.) for 90-day functional outcome, found that
on adjusted analyses only Interleukin-6 and NT-proBNP were
significantly related to poor 90-day outcome, but with no
significant improvement in predictive ability when added to age
plus NIHSS model [11].
In our study, adjusted TnI and fibrinogen were significantly
related to 30-day poor functional outcome of stroke. However,
upon adjustment for other biomarkers and clinical/echocardio-
Figure 2. C-reactive protein, fibrinogen, TnI and D-dimer sensitivity, specificity and associated criterion for unfavourable 30-day
outcome of ischemic stroke.
doi:10.1371/journal.pone.0106439.g002
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graphic variables, the CHA2DS2-VASc-F score (i.e., the ‘classic’
score plus fibrinogen) was no longer significantly associated with
30-day poor outcome, in contrast to the CHA2DS2-VASc-T score
(i.e., the ‘classic’ score plus TnI). Cardiac troponin (a protein
involved in the heart muscle contraction) is a well established
indicator of myocardial damage, and elevations in troponin levels
have been observed in patients with acute MI, stable CAD, HF,
renal failure, pulmonary embolism, and even in elderly apparently
healthy individuals [32,33,37–42]. In addition, it has been shown
that more than half AF patients have detectable levels of TnI [36].
Importantly, troponin has been uniformly associated with worse
outcomes and increased mortality in all these cohorts, independent
of traditional major coronary risk factors [32,33,36–39].
Increased troponin T levels have been reported in 5–34% of
patients with AIS [43], and the elevation of troponin T was
associated with stroke severity, insular cortex lesions, short- and
long-term clinical outcome and increased risk of mortality, thus
indicating prognostic significance of increased troponin T in AIS
[43–47]. TnI increase in the AIS patients may be caused by the
coincident ACS with myocardial necrosis or by a neurogenic
cardiac damage due to autonomic imbalance in the acute stroke
setting [48,49]. It is not always possible to elucidate the exact cause
of elevated TnI an individual patient with AIS, and an ongoing
study will try to prospectively determine the frequency and
possible etiology of troponin elevation in a large cohort of AIS
patients, using coronary angiography [49]. In our study, all
patients with known CAD and those with clinical, electrocardio-
graphic and/or echocardiographic findings suggesting myocardial
ischemia or acute MI at baseline (or during the subsequent 4
weeks) were excluded, in an effort to eliminate the impact of
possible acute MI on short-term outcome of acute stroke
(nonetheless, we are aware of the possibility that some of our
patients could still suffer an unrecognized MI).
Overall, our findings suggest that regardless of the significant
association of high-sensitivity TnI and fibrinogen with short-term
functional outcome of AIS, these biomarkers do not significantly
improve the excellent predictive ability of the CHA2DS2-VASc
score alone. Hence, a routine measurement of cardiac TnI in
patients presenting with AIS does not seem justified unless an ACS
is suspected. Given the relatively small size of our study, these
findings (and their potential implications for treatment decisions)
need further evaluation in larger cohorts with acute ischemic
stroke.
Study limitations
This was a single centre study performed in a university hospital
and our findings might not be fully reflective of a high volume
centre setting [50], although a 8.8% in-hospital mortality in our
study is comparable to other reports [50,51]. Nonetheless, our
findings should be interpreted with some caution, given the
relatively small number of participants in our study. Since the
baseline NIHSS was not available for majority of our patients, the
results were not adjusted for stroke severity. The NIHSS has been
shown to be an important predictor of mortality in AIS [1,52], but
Figure 3. Pairwise comparison of Receiver-operator characteristic of fully adjusted TnI, ‘classic’ and composed scores for
unfavourable 30-day functional outcome of ischemic stroke.
doi:10.1371/journal.pone.0106439.g003
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less than 50% of hospitals participating in the Get With The
Guidelines – Stroke regularly reported patient NIHSS scores in a
recent study [48], and the CHA2DS2-VASc score has been shown
previously to be a good predictor of stroke outcome in a model
which included NIHSS [15]. In addition, although all patients in
our study underwent a 24-hour Holter monitoring, there is still a
possibility of undiagnosed AF, which could affect the outcomes.
Finally, the observational design of our study does not exclude a
possibility of patient selection bias and residual confounding,
although we have prospectively included consecutive patients
presenting with AIS during one calendar year.
Conclusion
High-sensitivity TnI, fibrinogen and the CHA2DS2-VASc score
predict 30-day unfavourable functional outcome of AIS regardless
of the presence or absence of AF and other cardiovascular
comorbidities or risk factors. The CHA2DS2-VASc score has
better predictive ability for stroke outcome than TnI or fibrinogen,
and adding these biomarkers to the CHA2DS2-VASc score does
not further improve the prediction of poor 30-day stroke outcome
in the absence of clinically evident CAD. The use of CHA2DS2-
VASc score could facilitate a simplified, quick and reliable initial
risk assessment of patients presenting with AIS.
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